Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on March 29, 2022. The filing serves to announce the company's financial results for the fourth quarter and the full fiscal year ended December 31, 2021. AgeX is an emerging growth company incorporated in Delaware, with its common stock trading on the NYSE American under the symbol AGE.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the provided source text. Consequently, no specific financial figures can be extracted from this document alone.
Material Changes
The filing does not provide specific data regarding material changes versus prior periods. It solely indicates that the company has released its Q4 and full-year 2021 results, the details of which are contained in the referenced press release.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks and uncertainties.
- Risk Factors: The company directs investors to its periodic reports filed with the SEC under the heading "Risk Factors" for additional details on factors that could cause actual results to differ materially from anticipated results.
- Outlook: No specific guidance or management commentary regarding future performance is provided in the text of this 8-K.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated March 29, 2022), as these numbers are not present in the 8-K text.
- Confirm the company name is AgeX Therapeutics, Inc. (Ticker: AGE), noting the discrepancy with the "Serina Therapeutics" name in the request metadata.
- Review the company's most recent 10-K or 10-Q filings for detailed "Risk Factors" and historical financial comparisons.
- Check the status of the company's emerging growth company election and any related accounting standard transitions.